A GLP-1 microdosing chart may help guide gradual dose titration, potentially reducing tolerability challenges that some patients experience
For example, SGLT2i use leads to a 33% reduction (95% CI 26, 38) in hospitalisation for heart failure (HF) and a 35% reduction (95% CI 19, 47) in the incidence of end-stage kidney disease (ESKD) [3, 4], and GLP-1 RA use leads to a 10% reduction (95% CI 2, 17) in myocardial infarction (MI) and a 17% reduction (95% CI 8, 24) reduction in stroke [2]
vattenextrakt av vxter* [tvblommiga toppar av flockarun (Centaurium erythraea Rafn) 27,5 mg, malrt (Artemisia absinthium L.) 27,5 mg, kardon (Cynara cardunculus L.) 27,4 mg, rot av gentiana (Gentiana lutea L
These injectable medicines mimic the action of naturally occurring GLP-1, a hormone produced in the intestine that plays a crucial role in regulating blood glucose and appetite
Ideal candidates are motivated, open to lifestyle changes, and willing to follow a structured program.